Kaken Pharmaceutical Co., Ltd. (TYO:4521)

Market Cap	144.85B +4.8%
Revenue (ttm)	86.47B +5.4%
Net Income	9.15B +1,305.8%
EPS	241.68 +1,318.3%
Shares Out	37.87M
PE Ratio	15.83
Forward PE	24.21
Dividend	190.00 (4.97%)
Ex-Dividend Date	Mar 30, 2027

Volume	77,100
Open	3,840.00
Previous Close	3,840.00
Day's Range	3,805.00 - 3,845.00
52-Week Range	3,585.00 - 4,445.00
Beta	0.08
Analysts	Hold
Price Target	4,575.00 (+19.61%)
Earnings Date	Nov 9, 2026

About Kaken Pharmaceutical

Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. The company offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Fiblast, a wound-healing agent; Ecclock for the treatment of primary axillary hyperhidrosis; Regroth, a periodontal regenerative agent; Hernicore for the treatment of lumbar disc herniation; and Seprafilm, an adhesion barrier used primarily in surger...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1917
• Employees: 1,114
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4521

Financial Performance

In fiscal year 2026, Kaken Pharmaceutical's revenue was 76.87 billion, a decrease of -18.25% compared to the previous year's 94.04 billion. Earnings were 2.14 billion, a decrease of -84.63%.

Analyst Summary

According to 4 analysts, the average rating for 4521 stock is "Hold." The 12-month stock price target is ¥4,575, which is an increase of 19.61% from the latest price.

Price Target

¥4,575

(19.61% upside)

Analyst Consensus: Hold

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 13, 2026

Data Sources Report a data error